



ASX release

19 May 2009

70% sales growth in FY09 expected

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has increased guidance for FY2009 sales revenue to more than \$11 million, up from \$10 million anticipated in February 2009. This represents an increase of 70% over FY2008 sales.

Duncan Ross, AtCor Medical President and CEO, said "We are pleased with the progress made to date in a challenging economic environment. This improvement in our rate of growth demonstrates the increasing success of our sales strategy, together with some gains from the weaker Australian dollar. Of particular note is the expansion of the pharmaceutical trials market, which also provides further endorsement of the importance of central blood pressures in disease management".

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects that cannot be detected with standard blood pressure monitoring. Central blood pressure has been found to be a superior predictor of cardiovascular events such as stroke, heart attack and kidney disease.

More than 1,900 SphygmoCor systems are currently in use worldwide at major medical and research institutions and in clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in the United States, Australia, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8874

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations

Ph: +61 (2) 8264 1004/ m. 0407 231 282 _

SphygmoCor[®] is a registered trademark of AtCor Medical Pty Ltd and its related entities.